ArticleTobacco induced diseases2026
Global, regional, and national burden of acute myeloid leukemia attributable to tobacco from 1990 to 2021, with future forecasts to 2050: A secondary dataset analysis of the Global Burden of Disease 2021 study.
Article in Tobacco induced diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcute myeloid leukemia (AML) is a major public health problem. However, the epidemiological pattern of the burden of AML attributable to tobacco globally remains unclear. This study aimed to characterize the global, regional, and national burden of AML attributable to tobacco from 1990 to 2021 and to forecast it to 2050.
methodsData were sourced from the Global Burden of Disease (GBD) study 2021, and secondary dataset analysis was used in the present research. Age-standardized rates of tobacco-attributable AML deaths and disability-adjusted life years (DALYs) were analyzed, with estimated annual percentage change (EAPC) calculated. Age-period-cohort (APC) analysis was performed to quantify the age, period, and birth cohort effects on AML attributable to tobacco. A Bayesian APC model was subsequently us ed to project the disease burden of attributable to tobacco between 2022 and 2050.
resultsFrom 1990 to 2021, the burden of AML attributable to tobacco globally presented downward trends. The age-standardized death rate (ASDR) decreased from 0.214 [95% uncertainty interval (UI): 0.08-0.35] per 100000 people in 1990 to 0.176 (95% UI: 0.062-0.307) per 100000 people in 2021. The high sociodemographic index (SDI) regions had the highest ASDR and age-standardized DALYs rate for AML attributable to tobacco in 2021. The greatest burden of AML attributable to tobacco was the age group of 70-74 years among the risk factors of AML; tobacco shared at 11.5% of global deaths. As for the age effect, death due to AML attributable to tobacco increased with age, rising slowly before 40 years of age and accelerating sharply thereafter. The ASDR for males decreased from 0.3 per 100000 people in 2021 to 0.24 per 100000 people in 2022.
conclusionsAlthough the burden of AML attributable to tobacco had been on a downward trend from 1990 to 2021, it is particularly prominent in high SDI regions, high-income regions, and the elderly population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.